Background:
People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers.
Objective:
To learn how well vaccines work in people who have certain types of blood cancers.
Eligibility:
Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas.
Design:
Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine.
Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose.
Participants will have pregnancy tests, if needed.
Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks.
Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional.
Participation will last for up to 5 years after each vaccine series is received.

开始日期2022-09-14

申办/合作机构

National Heart, Lung & Blood Institute

ACTRN12619000792123 / Suspended临床3期

A Phase IIIb-IV, Multicentre, Randomised, Open-label Study to Characterise the Reactogenicity of Afluria Quad Junior in Children 6 Months to Less Than 3 Years, and Afluria Quad in Children 3 Years to Less Than 9 Years Across Three Influenza Seasons

开始日期2019-05-22

申办/合作机构

Seqirus GmbH

NCT02914275 / Completed临床3期

A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age

This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.

开始日期2016-09-27

申办/合作机构

Seqirus GmbH

100 项与 Inactivated quadrivalent influenza vaccine (Seqirus GmbH) 相关的临床结果

登录后查看更多信息

100 项与 Inactivated quadrivalent influenza vaccine (Seqirus GmbH) 相关的转化医学

登录后查看更多信息

100 项与 Inactivated quadrivalent influenza vaccine (Seqirus GmbH) 相关的专利（医药）

登录后查看更多信息

407

项与 Inactivated quadrivalent influenza vaccine (Seqirus GmbH) 相关的文献（医药）

2024-12-31·Human vaccines & immunotherapeutics

No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial

Article

作者: Seifert, Harry ; Naficy, Abdi ; Leav, Brett ; Hastie, Andrew ; Mwakingwe-Omari, Agnes ; Miller, Jacqueline ; Anteyi, Kate ; Kuxhausen, Adrienne

The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). This was a phase 3, randomized, open-label study. Eligible adults aged ≥ 18 years were randomly assigned (1:1) to receive mRNA-1273 (50 µg) booster vaccination and QIV 2 weeks apart (Seq group) or concomitantly (Coad group). Primary objectives were non-inferiority of haemagglutinin inhibition (HI) and anti-Spike protein antibody responses in the Coad compared to Seq group. 497/498 participants were randomized and vaccinated in the Seq/Coad groups, respectively. The adjusted geometric mean titer/concentration ratios (95% confidence intervals) (Seq/Coad) for HI antibodies were 1.02 (0.89-1.18) for A/H1N1, 0.93 (0.82-1.05) for A/H3N2, 1.00 (0.89-1.14] for B/Victoria, and 1.04 (0.93-1.17) for B/Yamagata; and 0.98 (0.84-1.13) for anti-Spike antibodies, thus meeting the protocol-specified non-inferiority criteria. The most frequently reported adverse events in both groups were pain at the injection site and myalgia. The 2 groups were similar in terms of the overall frequency, intensity, and duration of adverse events. In conclusion, co-administration of mRNA-1273 booster vaccine with QIV in adults was immunologically non-inferior to sequential administration. Safety and reactogenicity profiles were similar in both groups (clinicaltrials.gov NCT05047770).

2024-12-31·Human Vaccines & Immunotherapeutics

Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea

Article

作者: Song, Youngji ; Shim, Eunha

South Korea's National Immunization Program administers the quadrivalent influenza vaccine (QIV) to manage seasonal influenza, with a particular focus on the elderly. After reviewing the safety and immune response triggered by the adjuvanted QIV (aQIV) in individuals aged 65 and older, the Ministry of Food and Drug Safety in Korea approved its use. However, the extensive impact of aQIV on public health is yet to be fully understood. This study assessed the cost-effectiveness of replacing QIV with aQIV in South Korean adults aged 65 years and older. A dynamic transmission model, calibrated with national influenza data, was applied to compare the influence of aQIV and QIV on older adults and the broader population throughout a single influenza season. This study considered both the direct and indirect effects of vaccination on the elderly. We derived the incremental cost-effectiveness ratios (ICERs) from quality-adjusted life-years (QALYs) and costs incurred, validated through a probabilistic sensitivity analysis with 5,000 simulations. Findings suggest that transitioning to aQIV from QIV in the elderly would be cost-effective, particularly if aQIV's efficacy reaches or exceeds 56.1%. With an ICER of $29,267/QALY, considerably lower than the $34,998/QALY willingness-to-pay threshold, aQIV presents as a cost-effective option. Thus, implementing aQIV with at least 56.1% efficacy is beneficial from both financial and public health perspectives in mitigating seasonal influenza in South Korea.

2024-12-01·BIORESOURCE TECHNOLOGY

Pilot scale production of high-content mycoprotein using Rhizopus microsporus var. oligosporus by submerged fermentation and agro-industrial by-products

Article

作者: Rosa, Rosimeire Takaki ; Furlan, Orozimbo ; Michelotto, Pedro Vicente ; Bianchini, Luiz Fernando ; de Oliveira, Nicoly Subtil ; de Paula, Rafaela Caldas ; Weber, Saulo Henrique ; Rosa, Edvaldo Antonio Ribeiro

While mycoprotein has gained traction as a human food source, its potential as a nutrient for animals remains largely unexplored. The mycoprotein-producing Rhizopus microsporus var. oligosporus, a fungus traditionally used for human food in Indonesia, is promising. It could revolutionise animal nutrition once it is Generally Recognized as Safe (GRAS) and is a biosafety level 1 (BSL1) organism. To enhance sustainably, we propose using sugar cane molasses (SM) and corn steep liquor (CSL) as nutrient sources. Also, we investigated the growth of R. microsporus var. oligosporus in five 14 L external-loop airlift bioreactors using CSL as the sole nutrient source. After 96 h of fermentation, at 25 °C and 0.5 vvm, the mycelium produced had an average biomass yield of 38.34 g L^-1, with 70.18 % (m v^-1) crude protein (mycoprotein). This bioprocess, which is scalable and economically viable, produces high amounts of mycoprotein for animal feed using CSL, a cost-effective agro-industrial by-product, providing a practical solution to the growing demand for animal protein.

项与 Inactivated quadrivalent influenza vaccine (Seqirus GmbH) 相关的新闻（医药）

2024-10-18

·EndPoints

EMA again recommends against authorization for PTC Therapeutics' Translarna

The European Medicines Agency’s human medicines committee again decided not to recommend the renewal of the conditional marketing authorization for PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna. The treatment has gone through multiple reviews by the committee. Friday’s decision is the fourth time the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended against the drug. The CHMP first decided against Translarna in September 2023, then confirmed that decision in January 2024, following a re-examination requested by PTC Therapeutics. In June, the committee reviewed the drug after the European Commission asked the committee to consider additional data — but the committee’s decision remained the same. PTC Therapeutics asked the committee again to reconsider in July, which led to this fourth decision. Since its initial authorization in 2014, PTC Therapeutics has carried out two more studies in an attempt to show the drug’s effectiveness. The first study failed to confirm the efficacy of the treatment, though the data suggested that a subgroup of patients — those with a progressive decline in their ability to walk — might see more efficacy. A second study did not reach statistical significance in that subgroup of patients. The drug will remain available while the EMA reviews CHMP’s recommendation. “CHMP again based its decision on the results of the primary analysis subpopulation of Study 041 instead of the totality of evidence for Translarna,” PTC Therapeutics CEO Matthew Klein said in a statement . Leerink Partners wrote Friday that they expect this to be “the final negative opinion,” adding that although PTC Therapeutics resubmitted an NDA to the FDA in late July, there have been no more updates in the US, and they “remain skeptical on the likelihood of US approval.” In addition to the Translarna decision, here’s a look at the medicines that CHMP recommended ahead of a potential thumbs-up from the European Commission:

申请上市上市批准

2024-10-18

·PRNewswire

New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza

Results of the first season of a randomized study showed adjuvanted and high-dose influenza vaccines did not differ in effectiveness against PCR-confirmed influenza. This is the first randomized study to evaluate the relative vaccine effectiveness of adjuvanted influenza vaccines compared to high-dose influenza vaccines for prevention of lab-confirmed influenza. SUMMIT, N.J., Oct. 18, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced the first season (2023-2024 influenza season) results of the first pragmatic randomized study to evaluate the relative vaccine effectiveness (rVE) of adjuvanted inactivated influenza vaccine (aIIV) compared to high-dose inactivated influenza vaccine (HD-IIV) for prevention of lab-confirmed influenza. Results for the first season demonstrated that adjuvanted and high-dose influenza vaccines did not differ in effectiveness against Polymerase Chain Reaction (PCR)-confirmed influenza with a rVE of aIIV vs HD-IIV of 1.5% (95% confidence interval: -8.4 to 10.5) among adults 65 years of age and older. In addition, there was no difference in effectiveness between aIIV and HD-IIV for the prevention hospitalization or emergency department visits for PCR-confirmed influenza, and hospitalization for all-cause community-acquired pneumonia. This study is a collaborative study between CSL Seqirus and a large health system. The data was presented during an oral presentation this week at the IDWeek 2024 conference taking place in Los Angeles, California from October 16-19, 2024. The current findings of this pragmatic study align with previous research based on diagnostic and test confirmed outcomes, systematic reviews and meta-analyses which have generally shown comparable effectiveness between aIIV and HD-IIV influenza vaccines. The findings also support the current U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommendation that preferentially recommends any adjuvanted or higher-dose influenza vaccines for adults 65 years of age and older. The collaborative study is being conducted as a two-season pragmatic randomized study with approximately 480,000 individuals 65 years of age and older anticipated each season throughout facilities within a large health system. The second season and pooled season analyses will be performed following the end of the 2024-2025 season. "The findings of the first season of this study align with previous research based on diagnostic and test confirmed outcomes and systematic reviews and meta-analyses, which have shown comparable effectiveness between adjuvanted and high-dose influenza vaccines," says Ian McGovern, Associate Director, Center of Outcomes Research and Epidemiology. "Further, this data showcases the commitment of CSL Seqirus in generating high-quality real-world evidence data (RWE)." About the Study This study was a collaborative effort between CSL Seqirus and a large health maintenance organization within Northern California that both provides insurance and health care to their patient population. Individual medical facilities are randomized to administer either aIIV or HD-IIV and in alternating weeks which allowed individuals to be vaccinated as they would in routine clinical practice. Vaccinated individuals are tested for influenza per routine care using PCR for all tests. The study is designed to test the hypothesis that aIIV is non-inferior to HD-IIV, with a non-inferiority margin of -20% (i.e., lower bound of 95% CI needs to be above -20%). The primary outcome is PCR confirmed influenza in any setting. Secondary outcomes in each season include prevention of hospitalization or emergency department visits for PCR-confirmed influenza, and hospitalization for all-cause community-acquired pneumonia. A pooled analysis of the two seasons additionally includes the outcome of hospitalized PCR-confirmed influenza as well as analysis by age and risk groups. A total of 429,600 individuals were enrolled in the study for the first season: 212,877 adjuvanted inactivated influenza vaccine (aIIV); 216,723 high-dose inactivated influenza vaccine (HD-IIV). The randomization combined with broad patient inclusion results in a more representative but still balanced study population compared to a typical clinical study. The second season of the study is ongoing. Results may differ depending on the match between the vaccine and circulating influenza strains and other factors. This study was funded by CSL Seqirus. CSL Seqirus provided all the adjuvanted influenza vaccine doses to members of a large health system for this study. About Seasonal Influenza Influenza is a common, contagious seasonal respiratory disease that may cause severe illness and life-threatening complications in some people.1 Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases, death.1 Because transmission of influenza viruses to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.1 Preliminary estimates from the Centers for Disease Control and Prevention (CDC) report that during the 2023/24 influenza season, there were an estimated 390,000-830,000 influenza-related hospitalizations in the U.S.2 The CDC recommends annual vaccination for people aged six months and older, who do not have any contraindications.3 Since it takes about two weeks after vaccination for antibodies to develop in the body that help protect against influenza virus infection, it is recommended that people get vaccinated before influenza begins spreading in their community.3 The CDC recommends that for most people who need only 1 dose of influenza vaccine, vaccination should ideally happen in September or October.3 About CSL Seqirus CSL Seqirus is part of CSL (ASX: CSL). As a global leader in the protection of public health and one of the largest influenza vaccine providers in the world, CSL Seqirus is committed to preventing infectious diseases, like influenza and COVID-19, and is a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus offers a broad portfolio of innovative, differentiated vaccines in more than 20 countries around the world. For more information about CSL Seqirus, visit . About CSL CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit csl.com/we-are-csl/vita-original-stories and follow us on x.com/CSL. For more information about CSL, visit . Intended Audience This press release is issued from CSL Seqirus in Summit, New Jersey, USA and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved CSL Seqirus products may vary from country to country. Please consult your local regulatory authority on the approval status of CSL Seqirus products. Forward-Looking Statements This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. MEDIA CONTACT Tiffany Cody +1 (908) 370-1863 [email protected] SOURCE CSL Seqirus WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗临床结果

2024-10-04

·PRNewswire

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza

CSL Seqirus has received a Biomedical Advanced Research and Development Authority (BARDA) award to complete the fill and finish process for additional pre-pandemic vaccines to further support the U.S. government's outbreak and preparedness response. BARDA has requested adjuvanted H5N1 pre-pandemic vaccines and additional H5N8 antigen as part of its decision to expand its portfolio of pre-pandemic vaccines. This $34 million investment is the sixth avian influenza pandemic preparedness award made to CSL Seqirus by BARDA. SUMMIT, N.J., Oct. 4, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). This latest acquisition of pre-pandemic vaccine will further supplement BARDA's stockpile of vaccine to support the U.S. government's pre-pandemic response to avian influenza. "As a global leader in pandemic preparedness, this new award from BARDA emphasizes the value of collaboration in tackling global health threats as they emerge," said Marc Lacey, CSL Seqirus, Global Executive Director for Pandemic. "We're proud to be a pandemic partner to over thirty governments globally and to do our part to help safeguard and protect public health." Under the terms of the $34 million award, CSL Seqirus will deliver approximately 3 million finished doses of MF59®-adjuvanted H5N1 pre-pandemic vaccine and manufacture an additional lot of H5N8 antigen. Evidence produced by the CDC indicates both the H5N1 strain and the H5N8 strain are similar to A(H5N1) strains circulating among U.S. dairy cattle and suggests that both strains could be expected to induce a degree of protection in vaccinated individuals.1,2 "Pandemic preparedness is a core part of who we are," said Jon Kegerise, Vice President of Manufacturing and Site Head at CSL Seqirus Holly Springs. "Our Holly Springs site was built to be able to deliver innovative pandemic solutions at industrial scale and speed." CSL Seqirus' manufacturing facility in Holly Springs, North Carolina, built through a public-private partnership established in 2009 with BARDA, is the largest cell-based influenza vaccine producer in the world and is the first such domestic facility in the U.S. It utilizes a highly scalable method of production and is currently positioned to deliver 150 million influenza vaccine doses to support an influenza pandemic response within six months of a pandemic declaration. After this, a second wave of manufacturing could be enabled to provide further pandemic vaccine as needed. Seasonal vaccine manufacturing provides an essential "warm base" alongside ongoing R&D activity with influenza strains of pandemic potential, component and raw material stockpiles, seed libraries and technological know-how to be pandemic ready and manufacture at scale. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contracts HHSO100200900101C and 75A50122D00004. About Pandemic Influenza Influenza is a contagious airborne respiratory disease.3,4 The risk of influenza-associated morbidity and mortality is greater with pandemic influenza than with seasonal influenza because there is likely to be little or no pre-existing immunity to the novel virus in the human population.5 The timing and severity of pandemic influenza is unpredictable. Four influenza pandemics have occurred over the past century, with the 1918 pandemic being the most severe in recent history, with an estimated mortality of up to 50 million people worldwide.6 About Avian Influenza Avian influenza spreads predominantly among birds.7 Avian influenza viruses do not normally infect humans; however, in rare cases humans have been infected with avian influenza viruses.8 Illness in humans from avian influenza has varied in levels of severity, from no symptoms or mild illness to severe disease and death.8 The spread of avian influenza from one human to another is very rare and typically has only spread to a few people.8 The recent rise in avian influenza among birds has been driven by highly pathogenic avian influenza (HPAI) A(H5N1) virus.9 CSL Seqirus recommends referring to the WHO statement, and CDC, ECDC or national guidance to gauge the levels of concern regarding the high levels of HPAI activity.10,11,12 About CSL Seqirus CSL Seqirus is part of CSL (ASX: CSL). As a global leader in the protection of public health and one of the largest influenza vaccine providers in the world, CSL Seqirus is committed to preventing infectious diseases, like influenza and COVID-19, and is a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus offers a broad portfolio of innovative, differentiated vaccines in more than 20 countries around the world. For more information about CSL Seqirus, visit CSL.com. About CSL CSL (ASX:CSL) (USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/we-are-csl/vita-original-stories and follow us on Twitter.com/CSL. For more information about CSL, visit . Intended Audience This press release is issued from CSL Seqirus in Summit, New Jersey, USA and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved CSL Seqirus products may vary from country to country. Please consult your local regulatory authority on the approval status of CSL Seqirus products. Forward-Looking Statements This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. ### USA-PAN-24-0003 MEDIA CONTACT Em Dekonor +44 (0)7920500496 [email protected] 1 Centers for Disease Control and Prevention (CDC). Technical Update: Summary Analysis of Genetic Sequences of Highly Pathogenic Avian Influenza A(H5N1) Viruses in Texas. Retrieved from . Accessed September 2024 2 CDC. Technical Report: June 2024 Highly Pathogenic Avian Influenza A(H5N1) Viruses. Retrieved from . Accessed September 2024 3 CDC. About Flu. Retrieved from: . Accessed September 2024 4 CDC. Key Facts About Influenza (Flu). Retrieved from: . Accessed September 2024 5 WHO. How pandemic influenza emerges. Retrieved from: . Accessed September 2024 6 WHO. Pandemic Influenza Risk Management: A WHO guide to inform and harmonize national and international pandemic preparedness and response. Retrieved from: . Accessed September 2024 7 CDC. Avian Flu, Information on bird flu. Retrieved from: . Accessed September 2024 8 CDC. What Causes Bird Flu Virus Infections in Humans. Retrieved from: . Accessed September 2024 9 CDC. Highly Pathogenic Avian Influenza A(H5N1) Virus in Animals: Interim Recommendations. Retrieved from: . Accessed September 2024 10 CDC. H5 Bird Flu: Current Situation. Retrieved from: . Accessed September 2024 11 FAO, WHO, WOAH. Ongoing avian influenza outbreaks in animals pose risk to humans. Retrieved from: . Accessed September 2024 12 European Centre for Disease Prevention and Control (ECDC). Avian influenza overview March – June 2024. Retrieved from: . Accessed September 2024 SOURCE CSL Seqirus WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗并购

100 项与 Inactivated quadrivalent influenza vaccine (Seqirus GmbH) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB01	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	澳大利亚	Seqirus Pty Ltd.	2016-07-22
甲型流感病毒感染	美国	Seqirus Pty Ltd.	2007-09-28
乙型流感病毒感染	美国	Seqirus Pty Ltd.	2007-09-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02255409 (CTgov)	临床3期	流感病毒感染	607	Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)	積艱襯膚製窪顧襯顧襯(簾窪蓋醖鑰廠顧憲衊廠) = 憲鏇簾構鬱襯衊廠鬱築窪艱願網壓餘製積憲願 (壓鹹襯觸選觸憲鹽鹹鏇, 願淵餘鏇糧夢夢範範憲 ~ 積獵簾製壓艱醖夢願選) 更多	-	2023-03-15
NCT01857297 (CTgov)	临床4期	流感病毒感染	120	CSL Influenza Vaccine (Adults (18 to 59 Years))	鬱選顧餘衊醖遞窪憲廠(艱淵鏇鬱鑰網構鬱壓夢) = 鏇壓鏇襯壓範憲積醖簾選衊築廠淵遞艱廠淵積 (願網鹽鹽憲艱網淵築膚, 膚簾衊壓繭齋遞網鑰鹹 ~ 鬱遞網鏇襯壓餘構憲窪) 更多	-	2014-01-15
				CSL Influenza Vaccine (Older Adults (60 Years or Older))	鬱選顧餘衊醖遞窪憲廠(艱淵鏇鬱鑰網構鬱壓夢) = 夢壓夢餘獵壓壓願構窪選衊築廠淵遞艱廠淵積 (願網鹽鹽憲艱網淵築膚, 齋糧餘餘鏇衊淵齋襯繭 ~ 壓衊艱繭鹽糧鑰鑰餘餘) 更多
NCT01591837 (CTgov)	临床4期	流感病毒感染	120	CSL Influenza Vaccine (Adults)	鏇餘憲遞壓積製廠餘廠(蓋顧鹽壓獵蓋繭鹽築網) = 鏇衊襯構淵鑰憲製鏇衊醖顧獵積選鬱廠繭壓鹹 (鏇淵壓鹽膚鬱觸願廠鏇, 選遞夢築範觸糧選淵膚 ~ 壓遞選膚鑰選觸窪積鹽) 更多	-	2013-11-18
				CSL Influenza Vaccine (Older Adults)	鏇餘憲遞壓積製廠餘廠(蓋顧鹽壓獵蓋繭鹽築網) = 襯繭鹹餘鬱艱餘餘鏇鏇醖顧獵積選鬱廠繭壓鹹 (鏇淵壓鹽膚鬱觸願廠鏇, 餘憲廠艱簾衊鹹壓蓋壓 ~ 築顧範鏇膚窪觸襯觸鬱) 更多
NCT01113580 (CTgov)	临床4期	流感病毒感染	120	CSL's 2010/2011 Formulation of Enzira® Vaccine (Adults)	鹽醖繭繭鬱築憲範範積(鹹構鬱簾艱遞簾鹹網製) = 製廠顧鏇觸積鏇糧築窪繭遞膚齋簾觸壓憲餘憲 (憲繭糧簾廠淵蓋淵鏇選, 簾廠選繭鏇蓋選築醖鏇 ~ 選鏇衊淵製選簾衊構夢) 更多	-	2012-07-18
				CSL's 2010/2011 Formulation of Enzira® Vaccine (Older Adults)	鹽醖繭繭鬱築憲範範積(鹹構鬱簾艱遞簾鹹網製) = 衊餘顧選夢獵窪衊築網繭遞膚齋簾觸壓憲餘憲 (憲繭糧簾廠淵蓋淵鏇選, 襯壓衊顧窪鏇鹹蓋廠鏇 ~ 築築願顧糧壓簾醖獵繭) 更多
NCT00959049 (CTgov)	临床3期	流感病毒感染	1,474	CSL's Influenza Virus Vaccine (Afluria) (Afluria Cohort A)	夢範艱齋獵醖憲醖鏇鹽(鏇鹹蓋遞夢觸鑰糧窪繭) = 積顧餘選築廠壓窪憲衊獵艱獵鏇膚鹽範簾鏇製 (艱鹽鹹蓋願夢鹹鹽膚選, 顧蓋衊餘網蓋淵觸蓋餘 ~ 鹽襯醖獵獵願觸顧淵繭) 更多	-	2011-07-29
				Influenza Virus Vaccine (Fluzone) (Fluzone Cohort A)	夢範艱齋獵醖憲醖鏇鹽(鏇鹹蓋遞夢觸鑰糧窪繭) = 製鹹膚鏇鏇壓廠醖鑰窪獵艱獵鏇膚鹽範簾鏇製 (艱鹽鹹蓋願夢鹹鹽膚選, 製鑰範襯鑰鑰廠鹹鑰築 ~ 齋醖鬱網艱鬱鏇衊鹹艱) 更多